Regeneron to Report Q3 2025 Earnings: Can It Beat Estimates Again?
Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is set to unveil its fiscal Q3 2025 earnings on October 28, 2025. Wall Street analysts hold a 'Moderate Buy' rating for REGN's stock, with a mean price target of $729.85, suggesting a 29.5% potential upside from current levels.
REGN has a history of beating Wall Street's bottom-line estimates, achieving this feat in three of the last four quarters. In the previous quarter, REGN's earnings of $12.89 per share surpassed consensus estimates by a significant 60.5%. The company's overall revenue also grew by 3.6% year-over-year to $3.7 billion in Q2 2025, exceeding analyst expectations by 10.2%.
Looking ahead, analysts expect REGN to report a profit of $7.80 per share in Q3 2025, although this represents a 33.5% decrease from the year-ago quarter. For the full fiscal year 2025, REGN is forecast to report a profit of $32.36 per share, down 16.2% from fiscal 2024.
Despite the expected decrease in earnings, REGN's stock surged 2.5% following its better-than-expected Q2 earnings release on August 1, 2025. However, REGN has declined 44.9% over the past 52 weeks, underperforming both the S&P 500 Index and the Health Care Select Sector SPDR Fund. With a market cap of $59.1 billion, investors await REGN's upcoming earnings announcement to gauge the company's future prospects.
